Zydus Blasts Takeda's Patent Abuse 'Blueprint' At 3rd Circ.
Zydus Pharmaceuticals Inc. has urged the Third Circuit to revive antitrust counterclaims accusing Takeda Pharmaceutical Co. Ltd. of using sham patent infringement allegations to artificially delay generic-drug competition, warning that Takeda's...To view the full article, register now.
Already a subscriber? Click here to view full article